For patients who develop resistance to crizotinib or cannot tolerate its side effects, alternative treatments are available. Next-generation ALK inhibitors such as ceritinib, alectinib, and lorlatinib have shown efficacy in overcoming resistance. Additionally, other targeted therapies and combination treatments are being explored in clinical trials to provide more options for patients.
